Tengion Inc

Tengion — Investor Presentation (January 2012)

24 slides from Tengion's investor presentation, Jan 9, 2012

  1. Slide 1: Regenerative medicine to life.

    erative medicine to life.

  2. Slide 2: Forward-looking Statements

    2 Forward-looking Statements Certain statements in this presentation may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although Tengion believes that these statements are based upon reasonable assumptions within the bounds of its kn

  3. Slide 3: Company Highlights

    3 Company Highlights Tengion products harness the body’s natural ability to regenerate § Unique and productive research platform Neo-Urinary Conduit provides alternative to standard of care for bladder cancer patients § Neo-Urinary Conduit avoids use of bowel tissue § Ongoing Phase 1 trial to enroll

  4. Slide 4: Integrated Platform Catalyzing Regeneration in the Body

    4 INTEGRATED PLATFORM Catalyzing Regeneration in the Body Industrialization Cells Biomaterials Surgical Implantation Humans have limited capacity to regenerate Our platform uniquely catalyzes human tissue regeneration Catalyzing Regeneration in the Body

  5. Slide 5: Tengion Product Pipeline

    5 Additional Platform Programs (not in active development) Lead Platform Programs Tengion Product Pipeline Peripheral Artery Bypass Advanced CKD Cystectomy due to Bladder Cancer Cystectomy Spina Bifida Spinal Cord Injured Short Bowel Syndrome Coronary Artery Bypass Vascular Access Graft Urge Inconti

  6. Slide 6: Regenerative medicine to life.

    erative medicine to life.

  7. Slide 7: Neo-Urinary Conduit: Initial Clinical Trial

    7 Neo-Urinary Conduit: Initial Clinical Trial Open label study to define surgical procedure and safety Up to 10 patients with primary bladder cancer requiring cystectomy Sequential enrollment of initial patients § Allows for modifications to surgical procedure as needed § Three patients implanted to

  8. Slide 8: Urologic Products to Enhance or Replace Bladder

    8 Urologic Products to Enhance or Replace Bladder Benefit of Tengion Products Current Standard of Care Primary Patient Populations (US and EU) Bowel used to create a tube to transport urine from ureters to abdominal wall into ostomy bag Neo-Urinary Conduit Phase I Bladder cancer (20K/yr) Bowel used

  9. Slide 9: Regenerative medicine to life.

    erative medicine to life.

  10. Slide 10: Neo-Kidney Augment Overview

    10 Neo-Kidney Augment Overview Intended to delay the need for dialysis or transplantation Biopsy Cell Isolation & Culture Cell Selection Dose Preparation Delivery (2-3 weeks) (<1 day) (2 weeks) 100,000 new dialysis patients each year in the US § 350,000 currently on dialysis § 20% annual mortality §

  11. Slide 11: Neo-Kidney Augment Preclinical Data

    11 Neo-Kidney Augment Preclinical Data Initial data published in September, 2010 § Aggressive preclinical rodent model of chronic kidney disease § Preserved functional kidney mass, slowed progression, improved survival at 6 months Diabetic kidney failure § Aggressive diabetic, obese, hypertensive ro

  12. Slide 12: NKA

    12 NKA NK A SHAM NX HEALTHY NX NX + NKA Renal cells delivered after chronic disease state established enhanced survival and renal function § sCREAT sustained at >200% Renal cells improved multiple structural and physiologic parameters § Enhanced survival – 100% vs. 0% (Nx) § Improved glomerular func

  13. Slide 13: Neo-Kidney Augment Preclinical Data

    13 Neo-Kidney Augment Preclinical Data Initial data published in September, 2010 § Aggressive preclinical rodent model of chronic kidney disease § Preserved functional kidney mass, slowed progression, improved survival at 6 months Diabetic kidney failure § Aggressive diabetic, obese, hypertensive ro

  14. Slide 14: Treatment Group 63-week Survival

    14 Treatment Group 63-week Survival Untreated OB ZSF1 20% (1/5) OB ZSF1 + NKA 100% (5/5) Obese Tx (n=7) Obese (n=5) Age (Weeks) Renal Cells improve kidney function over time Renal Cells support survival beyond 50% mortality time point for OB ZSF1

  15. Slide 15: Neo-Kidney Augment Preclinical Data

    15 Neo-Kidney Augment Preclinical Data Initial data published in September, 2010 § Aggressive preclinical rodent model of chronic kidney disease § Preserved functional kidney mass, slowed progression, improved survival at 6 months Diabetic kidney failure § Aggressive diabetic, obese, hypertensive ro

  16. Slide 16: Human Kidney Tissue Regeneration in Nude Rats

    16 Human Kidney Tissue Regeneration in Nude Rats Delayed progression of CKD and stabilized renal function Human-derived cells prevent renal failure in CKD Nude Rats for 3 mo. Human-derived cells improve CKD Nude Rat nephron function I-R/G Injury + Human Renal Cells I-R/G Injury Treatment 1 4 12 week

  17. Slide 17: Neo-Kidney Augment Preclinical Data

    17 Neo-Kidney Augment Preclinical Data Initial data published in September, 2010 § Aggressive preclinical rodent model of chronic kidney disease § Preserved functional kidney mass, slowed progression, improved survival at 6 months Diabetic kidney failure § Aggressive diabetic, obese, hypertensive ro

  18. Slide 18: Treated

    18 Treated Untreated Weeks Post Renal Cell Treatment Significant reduction in rate of tubular disease progression § Electrolyte,UPC p < 0.0001* Improvement and stabilization of glomerular filtration § Iohexol Clearance (p<0.07) #

  19. Slide 19: Mechanism of Action Studies

    19 Ilagan et al, Amer Soc of Nephrology, 2010; Bruce et al, Exp Biol, 2011; Kelley et al ISCT, 2010; Kelly et al TERMIS, 2010 Mechanism of Action Studies NKA modifying widely accepted mechanisms § Engraftment § Renal cells persist for at least 6 months at low levels § Expansion post-implantation § N

  20. Slide 20: Regenerative medicine to life.

    erative medicine to life.

  21. Slide 21: IP and Barriers to Entry

    IP and Barriers to Entry Issued patent protection plus recent applications pending ™ 28 US and 97 international patents and patent applications " Core patents cover composition, design and methods of manufacture* Urologic Franchise Neo-Kidney Augment Plus know-how, trade secrets and integrated capab

  22. Slide 22: Financial Overview

    22 Financial Overview Financial Overview September 30, 2011 Cash and Investments Long-Term Debt Adjusted Net Loss - YTD Outstanding Shares $20.3 M $5.3 M $18.2 M 23.9 M June 30, 2011 $25.2 M $5.6 M $13.1 M 23.5 M

  23. Slide 23: Summary

    23 Summary Tengion products harness the body’s natural ability to regenerate § Unique and productive research platform Neo-Urinary Conduit provides alternative to standard of care for bladder cancer patients § Up to 10 patients to be implanted in ongoing Phase 1 trial; data permitting, complete pati

  24. Slide 24: Regenerative medicine to life.

    erative medicine to life.

Tengion — Investor Presentation (January 2012) on 6ix